Fig. 4

Examines the relationship between angiogenesis, EMT genes, and immunotherapy. (A-B) Evaluation of the differences in immune cell infiltration across different clusters. (C) Percentage of tumor-infiltrating immune cells for each sample. (D) Assessment of patient responses to predicted immune checkpoint inhibitors in various clusters utilizing the TIDE algorithm. (E) Comparison of Temozolomide IC50 scores among clusters